Most Read Articles
01 Jun 2016
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Jackey Suen, 20 May 2015
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
01 Jun 2016
Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination therapy is currently recommended as first-line treatment in patients with chronic hepatitis C virus (HCV) infection, based on a review.

Combined glycyrrhizin, tenofovir therapy safe and effective in SAE of chronic hepatitis B

Jairia Dela Cruz
25 Jul 2017

Early introduction of glycyrrhizin in combination with tenofovir in the treatment of patients with severe acute exacerbation (SAE) of chronic hepatitis B (CHB) is safe and effective, reducing serum transaminases rapidly in the first 2 weeks when compared with tenofovir alone, according to the results of an open-label trial.

In a cohort of 60 patients (77 percent male) with SAE of CHB, those treated with tenofovir plus intravenous glycyrrhizin (glycyrrhizin arm; n=30) fared significantly better in terms of the primary endpoint of a reduction in serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and in model for end-stage liver disease (MELD) score compared with patients given tenofovir alone (tenofovir only arm; n=30). The reductions were observed at day 3 and were sustained thereafter until day 15 (p<0.05 for all).  [Clin Trans Gastroenterol 2017;doi:10.1038/ctg.2017.29]

Specifically, significant improvements in MELD score were observed as early as the first week of treatment in the glycyrrhizin arm, whereas no changes from baseline were seen at weeks 1 and 2 in the tenofovir only arm. By week 24, one patient (33 percent) in the glycyrrhizin arm died while three died and one underwent liver transplant in the tenofovir only arm.

MELD score emerged as an independent factor for mortality or receipt of liver transplantation (p=0.021) in multivariate Cox proportional hazards analysis. The rates of grade 3 hypertension, hypokalaemia and ascites did not differ significantly between the two treatment arms.

Patients in the glycyrrhizin arm had a mean age of 49.1 years, while those in the tenofovir only arm had a mean age of 45.3 years. Tenofovir was administered at 300 mg daily in both arms, while the glycyrrhizin arm was given 10 days of intravenous glycyrrhizin. Mean baseline MELD score was 16.7 in the glycyrrhizin arm vs 17.4 in the tenofovir only arm, with 13 overall having MELD score >20. All patients were followed for at least 24 weeks from treatment initiation.

“Despite no statistical significance in mortality/transplantation-free rate, our data provide the first evidence that glycyrrhizin can significantly improve MELD score, even in more severe cases with higher baseline MELD score (>20),” the investigators said.

“In general, glycyrrhizin was safe and well tolerated. Although glycyrrhizin could induce hypokalaemia (<3.5 mmol/l), most patients had a mild degree without clinical symptoms,” they added.

An aqueous extract of liquorice root, glycyrrhizin has been shown to be hepatoprotective in vitro. This effect is achieved by supposedly preventing changes in cell membrane permeability and providing membrane stabilization, as have been demonstrated in previous animal studies. [World J Gastroenterol 2007;13:462–466; Arch Histol Cytol 2008;71:163–178]

“In a recent small study, corticosteroid treatment in combination with nucleotide analogue has sufficient virological effect against SAE of CHB, and a rapid decline of HBV-DNA is conspicuous in [survivors]. However, the increased risk of infectious complications after corticosteroid treatment should be a serious concern, particularly because sepsis is one of the most important causes of death in CHB with SAE,” the investigators noted. [J Viral Hepat 2015;22:94–102; World J Gastroenterol 2012;18:5078–5083]

“By contrast, our study medication ‘glycyrrhizin’ appears to be safe and the expected side effects associated with pseudoaldosteronism are usually minor and reversible,” they said.

Given the presence of limitations in the study, including the relatively small sample size and a follow-up duration that prevented assessment of long-term impact of the study medication on progression of liver disease, the investigators said additional studies are warranted to further examine the survival benefit of glycyrrhizin in CHB with SAE.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2016
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Jackey Suen, 20 May 2015
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
01 Jun 2016
Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination therapy is currently recommended as first-line treatment in patients with chronic hepatitis C virus (HCV) infection, based on a review.